Artificial intelligence (AI) software developer Imbio has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for RV/LV Analysis, a cardiothoracic imaging AI algorithm.
Designed to provide automated assessment of potential right ventricular dilation, RV/LV Analysis calculates the ratio of the maximum diameter of the right versus the left ventricle of the heart on CT pulmonary angiography exams, according to the vendor. This RV/LV ratio is a patient risk indicator for various pulmonary conditions, including pulmonary embolism, Imbio said.
The company said that the software's results are automatically available for clinicians; a full report of quantitative findings is added to the patient's imaging study within minutes.
